Progesterone Alone for Hot Flashes: Three Trials With Different Results

Progesterone may be prescribed for different reasons: protecting the uterine lining during estrogen treatment, managing particular menstrual problems, or trying to relieve symptoms. Ask which job your prescription is intended to do before judging it against a hot-flash headline.

The studies here concern oral micronized progesterone used without estrogen. Their findings cannot be transferred to an over-the-counter cream or a different hormone regimen.

The first trial enrolled selected healthy postmenopausal women

A Canadian trial published in 2012 randomized 133 women aged 44–62, one to ten years after their final period, to 300 mg at bedtime or placebo for 12 weeks. Participants were nonsmokers without diabetes and were screened for cardiovascular risk.¹

Its primary outcome combined symptom frequency and severity: daytime frequency multiplied by severity, plus the corresponding nighttime values. Progesterone’s adjusted advantage was 4.3 score points, with a 95% confidence interval of 1.9–6.6 points favoring treatment. That is a symptom score, not 4.3 fewer flashes per day.¹

The main analysis included 114 women with sufficient diary data. Results support benefit in this selected population; they cannot establish benefit across every menopause stage or medical history.¹

The perimenopause trial missed its main outcome

The 2023 Canadian trial² randomized 189 women aged 35–58 who had menstruated within the previous year. After a baseline month, they received 300 mg at bedtime or placebo for three months.²

The third-month diary symptom score did not significantly differ between groups: the estimated difference was −1.51, with a 95% confidence interval from −3.97 to 0.95 and P=.222. The interval includes no treatment difference, but also a potentially useful benefit. The study was underpowered.²

An end-of-study questionnaire favored progesterone for perceived night-sweat improvement and sleep quality. Calendar-recorded sleep problems did not differ. These measures describe different aspects of symptoms and should be reported separately.²

The result is uncertain, rather than proof of reliable relief or proof that progesterone cannot help anyone in perimenopause.

A correction changed two secondary-outcome rows

In July 2024, the authors corrected Table 2: the group values for the Perimenopause Interference Questionnaire and PHQ-9 depression questionnaire had been placed in the wrong rows. The corrected interference means were 22.6 with progesterone and 28.2 with placebo; PHQ-9 means were 4.8 and 5.4. The published treatment comparisons and P values for those rows were unchanged.³

The correction does not turn the nonsignificant primary hot-flash/night-sweat outcome into a positive one. When reading summaries, check which questionnaire and outcome they describe.

The later German study stopped before adequate recruitment

The 2024 PROGEST study compared 200, 300 and 400 mg nightly with placebo for 12 weeks. It randomized only 55 women before stopping because recruitment was insufficient. There were 54 in the efficacy analysis and 44 protocol completers.⁴

Moderate-to-severe episodes decreased by 7.4 per day with placebo, versus 7.7, 8.3 and 9.0 in the ascending dose groups. None of the progesterone doses significantly outperformed placebo. Large decreases within treatment groups would give a misleading impression if the placebo decrease were omitted.⁴

The numerical pattern cannot establish a reliable dose advantage.⁴

One participant taking 400 mg fainted and was hospitalized after starting treatment. The investigator judged it unrelated to the medicine; treatment was discontinued. Rare-event and long-term risks remain unresolved.⁴

The US label lists other indications

The current US PROMETRIUM label, revised in 2026, lists prevention of endometrial hyperplasia in postmenopausal women with a uterus taking conjugated estrogens, and treatment of secondary amenorrhea. Hot-flash treatment with progesterone alone is not a listed indication. That is an off-label prescribing discussion, not a reason to change an existing prescription yourself.⁵

The label warns about dizziness and drowsiness, bedtime administration and caution with driving or machinery. PROMETRIUM contains peanut oil and must not be used by people allergic to peanuts. Check the exact product and ingredients with the pharmacist.⁵

Its contraindications include unexplained genital bleeding, breast cancer or its history, certain blood-clot and arterial-event histories, and liver disease. It advises prompt review of unusual vaginal bleeding. Those details belong in the prescribing decision; short trial follow-up cannot replace them.⁵

Keep symptom treatment, uterine protection and contraception separate

UK NHS⁶ guidance states that Utrogestan is not contraception. Pregnancy can remain possible while taking hormone therapy. If that applies to you, ask about a contraception plan.⁶

The NHS⁷ also emphasizes keeping the prescribed progestogen when taking systemic estrogen with a uterus, because unopposed estrogen can cause problems with the uterine lining. The progesterone-alone trials are not instructions to remove a component of your prescribed regimen.⁷

Bring a record of daytime flashes, nighttime awakenings, bleeding and next-day effects to the review. Ask what benefit the clinician expects, which alternatives fit your history, and when you will assess the response.

Chapter 10, “The Hormone Question,” in My Body Changed. Now What? uses the Change Map and Visit Brief to organize age, menopause stage, uterus status and relevant medical history. Those specifics are needed to apply the evidence to a prescription decision.